About 268 results

ALLMedicine™ Alveolar Soft Part Sarcoma Center

Research & Reviews  100 results

Advances in the management of alveolar soft part sarcoma.
Current Problems in Cancer; O'Sullivan Coyne G, Naqash AR et. al.

Jul 22nd, 2021 - Alveolar Soft Part Sarcoma is one of the less commonly diagnosed soft tissue sarcoma subtypes, an infrequent subtype within the already rare category of human malignancy of sarcoma. In this article we will summarize the histopathological features,...

Primary Intracerebral Alveolar Soft Part Sarcoma: Report of a Case and Review of the Li...
International Journal of Surgical Pathology; Caporalini C, Giordano F et. al.

Jun 19th, 2021 - Alveolar soft part sarcomas (ASPSs) are rare malignant tumors representing ∼1% of all soft tissue sarcomas. Most ASPS occurring in the central nervous system are metastases. In contrast, primary intracranial ASPSs are extremely rare and only 8 cas...

Microsurgical Management of Early Onset Alveolar Soft Part Sarcoma of the Oral Tongue: ...
The Annals of Otology, Rhinology, and Laryngology; Lucas JC, Karadaghy OA et. al.

May 29th, 2021 - Alveolar soft part sarcoma is a rare subset of soft tissue sarcomas, typically presenting in subjects 15 to 35 years of age. Usual presentation sites are the trunk, extremities, and the head and neck. Subjects younger than 5 years are rarely affec...

Imaging superiority of 68Ga-FAPI-04 over [18F]-FDG PET/CT in alveolar soft part sarcoma...
https://doi.org/10.1007/s00259-021-05388-y 10.1007/s00259-020-04769-z 10.2967/jnumed.119.227967
European Journal of Nuclear Medicine and Molecular Imaging; Zhou X, Wang S et. al.

May 14th, 2021 - Imaging superiority of 68Ga-FAPI-04 over [18F]-FDG PET/CT in alveolar soft part sarcoma (ASPS).|2021|Zhou X,Wang S,Zhu H,Yang Z,Li N,|

see more →

Clinicaltrials.gov  4 results

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Apr 20th, 2020 - Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevan...

A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)

Jan 24th, 2019 - Patients aged 16 years and older with a histologically confirmed diagnosis of ASPS will be recruited. Eligible patients will be randomised to receive cediranib (30 mg daily po) or placebo (30 mg daily po) in a 2:1 ratio. At 24 weeks post randomisa...

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Oct 17th, 2018 - Background: Alveolar soft part sarcoma is a type of cancer that develops in tissues that connect, support, or surround other organs in the body. It relies heavily on new blood vessels to grow and spread through the body. There is no effective syst...

Phase 2 Study in Patients With MiT Tumors

Feb 8th, 2013 - This is a multi-center, single arm, two-stage phase 2 study of ARQ 197 in patients with microphthalmia transcription factor associated (MiT) tumors. ARQ 197 is a novel small molecule drug designed to block the activity of c-Met, which is thought t...

see more →

News  3 results

TKIs and immunotherapy hold promise for alveolar soft part sarcoma
Roxanne Nelson

Oct 23rd, 2018 - Alveolar soft part sarcoma (ASPS) has often proven to be resistant to conventional doxorubicin-based chemotherapy, but tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) may provide new treatment strategies for this rare typ.

Primary Alveolar Soft Part Sarcoma of Chest Wall: A Case Report and Review of the Literature

Jul 5th, 2006 - Discussion The exact cause of ASPS is not entirely understood; however, studies indicate that genetic alterations may play a role. Certain inherited conditions are associated with an increased risk of developing soft-tissue sarcomas, including Li-...

Primary Alveolar Soft Part Sarcoma of Chest Wall: A Case Report and Review of the Literature

Jul 5th, 2006 - Introduction Alveolar soft part sarcoma (ASPS), also called alveolar soft-tissue sarcoma (ASTS), is a rare malignant soft-tissue neoplasm, which was first described by Christopherson and colleagues[1] in 1952. Its prevalence is less than 1% of all...

see more →